BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 27798928)

  • 1. Signet Ring Cells and Efficacy of First-line Chemotherapy in Advanced Gastric or Oesogastric Junction Adenocarcinoma.
    Lemoine N; Adenis A; Bouche O; Duhamel A; Heurgue A; Leteurtre E; Amela E; Salleron J; Hebbar M
    Anticancer Res; 2016 Oct; 36(10):5543-5549. PubMed ID: 27798928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach?
    Heger U; Blank S; Wiecha C; Langer R; Weichert W; Lordick F; Bruckner T; Dobritz M; Burian M; Springfeld C; Grenacher L; Siewert JR; Büchler M; Ott K
    Ann Surg Oncol; 2014 May; 21(5):1739-48. PubMed ID: 24419755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced gastric carcinoma with signet ring cell histology.
    Li C; Kim S; Lai JF; Hyung WJ; Choi WH; Choi SH; Noh SH
    Oncology; 2007; 72(1-2):64-8. PubMed ID: 18004078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase III, randomised trial of avelumab versus physician's choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300.
    Bang YJ; Ruiz EY; Van Cutsem E; Lee KW; Wyrwicz L; Schenker M; Alsina M; Ryu MH; Chung HC; Evesque L; Al-Batran SE; Park SH; Lichinitser M; Boku N; Moehler MH; Hong J; Xiong H; Hallwachs R; Conti I; Taieb J
    Ann Oncol; 2018 Oct; 29(10):2052-2060. PubMed ID: 30052729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Prognostic Value of Signet-Ring Cell Histology in Resected Gastric Adenocarcinoma.
    Postlewait LM; Squires MH; Kooby DA; Poultsides GA; Weber SM; Bloomston M; Fields RC; Pawlik TM; Votanopoulos KI; Schmidt CR; Ejaz A; Acher AW; Worhunsky DJ; Saunders N; Swords D; Jin LX; Cho CS; Winslow ER; Cardona K; Staley CA; Maithel SK
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S832-9. PubMed ID: 26156656
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma: a multicenter comparative study.
    Messager M; Lefevre JH; Pichot-Delahaye V; Souadka A; Piessen G; Mariette C;
    Ann Surg; 2011 Nov; 254(5):684-93; discussion 693. PubMed ID: 22005144
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological Characteristics and Survival Outcomes of Primary Signet Ring Cell Carcinoma in the Stomach: Retrospective Analysis of Single Center Database.
    Liu X; Cai H; Sheng W; Yu L; Long Z; Shi Y; Wang Y
    PLoS One; 2015; 10(12):e0144420. PubMed ID: 26642199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of preoperative radiochemotherapy on survival in advanced esophagogastric junction signet ring cell adenocarcinoma.
    Bekkar S; Gronnier C; Messager M; Robb WB; Piessen G; Mariette C;
    Ann Thorac Surg; 2014 Jan; 97(1):303-10. PubMed ID: 24200394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Signet ring cell histology is an independent predictor of poor prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation.
    Piessen G; Messager M; Leteurtre E; Jean-Pierre T; Mariette C
    Ann Surg; 2009 Dec; 250(6):878-87. PubMed ID: 19855261
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is signet-ring cell carcinoma a specific entity among gastric cancers?
    Voron T; Messager M; Duhamel A; Lefevre J; Mabrut JY; Goere D; Meunier B; Brigand C; Hamy A; Glehen O; Mariette C; Paye F
    Gastric Cancer; 2016 Oct; 19(4):1027-1040. PubMed ID: 26606931
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Post progression survival analysis of metastatic gastric and gastroesophageal junction cancer patients after second-line treatment.
    Turkmen E; Erdogan B; Kodaz H; Hacibekiroglu I; Onal Y; Uzunoglu S; Kilic N; Cicin I
    Acta Gastroenterol Belg; 2016; 79(2):211-5. PubMed ID: 27382940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological characteristics of signet ring cell carcinoma of the stomach.
    Kim DY; Park YK; Joo JK; Ryu SY; Kim YJ; Kim SK; Lee JH
    ANZ J Surg; 2004 Dec; 74(12):1060-4. PubMed ID: 15574148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study.
    Iveson T; Donehower RC; Davidenko I; Tjulandin S; Deptala A; Harrison M; Nirni S; Lakshmaiah K; Thomas A; Jiang Y; Zhu M; Tang R; Anderson A; Dubey S; Oliner KS; Loh E
    Lancet Oncol; 2014 Aug; 15(9):1007-18. PubMed ID: 24965569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neoadjuvant Therapy Improves Outcomes in Locally Advanced Signet-Ring-Cell Containing Esophagogastric Adenocarcinomas.
    Heger U; Sisic L; Nienhüser H; Blank S; Hinz U; Haag GM; Ott K; Ulrich A; Büchler MW; Schmidt T
    Ann Surg Oncol; 2018 Aug; 25(8):2418-2427. PubMed ID: 29855828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma.
    van Hootegem SJM; Smithers BM; Gotley DC; Brosda S; Thomson IG; Thomas JM; Gartside M; van Lanschot JJB; Lagarde SM; Wijnhoven BPL; Barbour AP
    Ann Surg Oncol; 2019 Aug; 26(8):2375-2384. PubMed ID: 30941657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adenocarcinoma of the esophagus with signet ring cell features portends a poor prognosis.
    Enlow JM; Denlinger CE; Stroud MR; Ralston JS; Reed CE
    Ann Thorac Surg; 2013 Dec; 96(6):1927-32. PubMed ID: 23987898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Does early signet ring cell gastric carcinoma carry a worse prognosis?].
    Triboulet JP; Gronnier C; Messager M; Piessen G; Mariette C;
    Bull Acad Natl Med; 2013 Feb; 197(2):443-55; discussion 455-6. PubMed ID: 24919373
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of docetaxel- and oxaliplatin-based adjuvant chemotherapy in postgastrectomy gastric cancer patients reveals obvious survival benefits in docetaxel-treated mixed signet ring cell carcinoma patients.
    Chen L; Shi Y; Yuan J; Wu Q; Han Y; Qin R; Jia B; Wei B; Wei L; Dai G; Jiao S
    Med Oncol; 2014 Sep; 31(9):159. PubMed ID: 25119501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is the negative prognostic impact of signet ring cell histology maintained in early gastric adenocarcinoma?
    Gronnier C; Messager M; Robb WB; Thiebot T; Louis D; Luc G; Piessen G; Mariette C;
    Surgery; 2013 Nov; 154(5):1093-9. PubMed ID: 24075273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy.
    Kanagavel D; Pokataev IA; Fedyanin MY; Tryakin AA; Bazin IS; Narimanov MN; Yakovleva ES; Garin AM; Tjulandin SA
    Ann Oncol; 2010 Sep; 21(9):1779-1785. PubMed ID: 20150573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.